Some analysts estimate that more than 100 incretin-modulating candidates, across GLP-1, GIP, glucagon, amylin, and novel multi-agonist combinations, are now in development. Over 50 companies are vying for a slice of this opportunity, from biotechnology newcomers to multinational giants. …
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News